People Business
The former promoters of Ranbaxy, Malvinder Singh and Shivinder Singh, suffered a major setback when an arbitration tribunal in Singapore asked them to pay 56.2 billion Yen (nearly Rs 3,500 crore) to Daiichi Sankyo for concealing key facts during the sale of their controlling stake in the company.

- May 14, 2016,
- Updated May 18, 2016 10:11 AM IST
No Pain Relief
The former promoters of Ranbaxy, Malvinder Singh and Shivinder Singh, suffered a major setback when an arbitration tribunal in Singapore asked them to pay 56.2 billion Yen (nearly Rs 3,500 crore) to Daiichi Sankyo for concealing key facts during the sale of their controlling stake in the company. Daiichi had accused the brothers of misrepresenting the problems Ranbaxy was facing when the Japanese firm acquired it in 2008. The Singh brothers sold off their entire stake of about 35 per cent in Ranbaxy for $2.4 billion (around Rs 10,000 crore) to Daiichi Sankyo. While Malvinder Singh currently heads Fortis Healthcare, his brother Shivinder has stepped down from the executive role in the group.
Call Dropped By Supreme Court
New Revelations
Following Chinese Steps
Saying Hi to Tata
No Pain Relief
The former promoters of Ranbaxy, Malvinder Singh and Shivinder Singh, suffered a major setback when an arbitration tribunal in Singapore asked them to pay 56.2 billion Yen (nearly Rs 3,500 crore) to Daiichi Sankyo for concealing key facts during the sale of their controlling stake in the company. Daiichi had accused the brothers of misrepresenting the problems Ranbaxy was facing when the Japanese firm acquired it in 2008. The Singh brothers sold off their entire stake of about 35 per cent in Ranbaxy for $2.4 billion (around Rs 10,000 crore) to Daiichi Sankyo. While Malvinder Singh currently heads Fortis Healthcare, his brother Shivinder has stepped down from the executive role in the group.
Call Dropped By Supreme Court
New Revelations
Following Chinese Steps
Saying Hi to Tata
